慢乙肝和慢重肝患者趋化因子的表达差异及干扰素治疗后的变化  

Differential expression of chemokines in chronic HBV infection with different clinical phenotype and the changes of chemokines in patients with chronic hepatitis B by interferon therapy

作　　者：尚鹏程[1,2] 许娇 裴晓方[1] 

机构地区：[1]四川大学华西公共卫生学院(华西第四医院),四川成都610041 [2]成都市公共卫生临床医疗中心,四川成都610041

出　　处：《现代预防医学》2017年第5期882-885,共4页Modern Preventive Medicine

摘　　要：目的探讨外周血趋化因子CCL20、CXCL9及CXCL11在HBV慢性感染后不同临床分型间的表达差异以及干扰素治疗对慢乙肝患者外周血中这些趋化因子水平的影响。方法采用酶联免疫吸附分析(enzyme linked immunosorbent assay ELISA)检测外周血趋化因子CCL20、CXCL9及CXCL11在慢乙肝组、慢重肝组和健康对照组之间的差异;对30例慢乙肝患者用干扰素治疗,于治疗后第4周、第12周、第24周和第48周,采集外周血,检测上述趋化因子的水平,以及ALT、HBV-DNA和HBs Ag的变化。结果慢乙肝组、慢重肝组和对照组间外周血趋化因子CCL20、CXCL9、CXCL11水平差异有统计学意义(F分别为3.802、2.573、2.809;P分别为0.024、0.037、0.043),且慢重肝组高于慢乙肝组,慢乙肝组高于对照组;经干扰素治疗12周、24周和48周后的慢乙肝患者,其外周血趋化因子CCL20、CXCL9及CXCL11的表达也降低(P<0.05),同时发现ALT、HBV-DNA以及HBs Ag均有明显下降。结论趋化因子CCL20、CXCL9及CXCL11在HBV慢性感染的不同临床分型间存在差异,干扰素治疗可以降低慢乙肝患者的炎症反应和HBV病毒水平。Objective To investigate the difference of chemokine CCL20 CXCL9 and CXCL11 in peripheral blood,in chronic HBV infection with different clinical phenotype and the effect of interferon therapy on the levels of these chemokines in peripheral blood of patients with chronic hepatitis B. Methods Enzyme linked immunosorbent assay（ ELISA） was used to detect chemokine CCL20,CXCL9 and CXCL11 in peripheral blood in chronic hepatitis B group,chronic severe hepatitis group and healthy control group. Dynamically observe peripheral blood chemokine CCL20,CXCL9 and CXCL11 levels of changes,as well as changes in ALT,HBV-DNA and HBs Ag of 30 cases of interferon treatment of chronic hepatitis B patients at 4 weeks,12 weeks,24 weeks and 48 weeks. Results The chemokines CCL20,CXCL9 and CXCL11 in peripheral blood showed a significant difference in chronic hepatitis B group,chronic severe hepatitis group and the control group（ F： 3. 802,2. 573,2.809,respectively; P： 0. 024,0. 037,0. 043,respectively）. Chronic severe hepatitis group was higher than chronic hepatitis B group,and chronic hepatitis B group was higher than control group. After 12 weeks,24 weeks and 48 weeks,the expression of CCL20,CXCL9 and CXCL11 in the peripheral blood of patients with chronic hepatitis B by interferon therapy decreased（ P 0.05）,and at the same time,ALT,HBV-DNA and HBs Ag significantly decreased. Conclusion Chemokines CCL20,CXCL9 and CXCL11 are different in the different clinical phenotypes of chronic HBV infection. Interferon therapy can reduce the inflammatory reaction and HBV virus levels in patients with chronic hepatitis B.

关 键 词：HBV感染 CXCL9 CXCL11 CCL20 干扰素 

分 类 号：R113[医药卫生—公共卫生与预防医学]